Results 41 to 50 of about 9,561 (186)
Construction of pathogenic Sec16a mutation mouse model using CRISPR/Cas9
Animal Models and Experimental Medicine, EarlyView.Yaqiang Hu et al. engineered a pathogenic Sec16a mutant mouse model using CRISPR/Cas9 technology. They observed that the Sec16a mutant mice displayed diminished learning and memory capabilities, along with a limb‐clasping phenotype upon tail suspension.
Yaqiang Hu +6 more
wiley +1 more source
Controlling the Field: Memory, Labor, and Ethics in Oral Histories of Brazilian Human Genetics
Berichte zur Wissenschaftsgeschichte, EarlyView.This article examines how oral histories of twentieth‐century human genetics in Brazil reveal the politics of memory of fieldwork. Through a comparative analysis of interviews with prominent geneticist Francisco M. Salzano and technician Girley V. Simões, who worked with him for most of his career, this study explores the narrative strategies each ...
Rosanna Dent +1 more
wiley +1 more source
Biotechnology and Bioengineering, EarlyView.ABSTRACT Adeno‐associated viral (AAV) vectors for gene therapy are becoming integral to modern medicine, providing therapeutic options for diseases once deemed incurable. Currently, viral vector purification is a critical bottleneck in the gene therapy industry, impacting product efficacy and safety as well as accessibility and cost to patients ...
Kelvin P. Idanwekhai +9 more
wiley +1 more source
Acquired Factor VIII Inhibitors: Three Cases
Turkish Journal of Hematology, 2013 Acquired hemophilia A is a rare, but devastating bleeding disorder caused by spontaneous development of autoantibodies directed against coagulation factor VIII.
Tay Za Kyaw +3 more
doaj +1 more source
Acquired Hemophilia A and urothelial carcinoma
Journal of Community Hospital Internal Medicine Perspectives, 2021 Acquired Hemophilia A (AHA) is a rare entity, resulting from the production of autoantibodies against Factor VIII of the coagulation cascade. These autoantibodies may develop in response to autoimmune conditions, drugs, neoplastic diseases, and pregnancy.
Fadi Taza +3 more
doaj +1 more source
Hematology & Transfusion International Journal, 2017 Acquired hemophilia A AHA is a rare but potentially life threatening bleeding disorder caused by the development of auto antibodies against circulating factor VIII Age distribution is bimodal with a first peak occurring among young women in postpartum period and a second major peak among elderly patients Fifty percent of cases are idiopathic ...
openaire +1 more source
Acquired hemophilia A: case report [PDF]
Vnitřní lékařství, 2018 Case report of a 74-year-old male with acquired hemophilia A, whose etiology was not found, confirmed by hemocoagulation examinations, with clinical manifestation of protracted macroscopic hematuria, spontaneous skin and intramuscular bleedings. Treatment comprised conservative therapy administration of hemostyptics, red blood cells transfusions ...
Štefan, Sotak, Miriam, Mitníková
openaire +2 more sources
Antithrombin: Deficiency, Diversity, and the Future of Diagnostics
Mass Spectrometry Reviews, EarlyView.ABSTRACT Our healthcare system provides reactive sick‐care, treating patients after symptoms have appeared by prescription of generic and often suboptimal therapy. This strategy brings along high costs and high pressure which is not sustainable.
Mirjam Kruijt +2 more
wiley +1 more source
Sperm Sexing in Selected Animals and Humans: Methods, Applications, and Future Prospects
Andrology, EarlyView.ABSTRACT Background Sperm sexing is a technique that enables the selection of offspring sex by sorting spermatozoa based on their sex chromosomes. This technology has gained increasing attention due to its potential applications in both animal breeding and human‐assisted reproduction.
Domrazek Kinga, Jurka Piotr
wiley +1 more source
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
British Journal of Pharmacology, EarlyView.Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos +16 more
wiley +1 more source